| Indication | Oncology |
| Status | – CDMO Tech-transfer ongoing.
– ODD granted on December 23th, 2020. |
| Product Advantages | Handa is utilizing its ONCORE™ technology to develop improved versions of Oncology drug for reducing the risk associated with sever side effect and improve bioavailability. |
| Potential Market | Oncology market value is $133 billion in 2017. |
?
R&D
HND-027
